CSPC Innovation Pharmaceutical, a subsidiary of CSPC Pharma, announced that the market application of Enlonabizumab injection (tradename: Enshuxing) developed by its subsidiary Jushil Biopharmaceuticals has recently received conditional approval from the National Medical Products Administration.
新诺威：控股子公司获得药物上市申请附条件批准
CSPC Innovation Pharmaceutical: the controlling subsidiary has received conditional approval for drug listing application.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.